Medicare Rx Cost Controls Could Drive "Breakthrough" R&D - Rep. Stark
Medicare prescription drug budgets should be designed to encourage research into "truly new products," Rep. Stark (D-Calif.) suggested in an Aug. 8 memorandum submitted to the HHS drug pricing conference in Washington, D.C.
You may also be interested in...
Deeply discounted launch prices for brand name pharmaceuticals are rare because promotional costs are high regardless of price, AstraZeneca Director of Public Policy Robert Freeman, PhD, suggested during the HHS conference on drug pricing Aug. 8 in Washington, D.C.
Administered pricing for a Medicare drug benefit could result in "inappropriate patterns of investment" in pharmaceutical research and development, the Medicare Payment Advisory Commission's June 1 report to Congress states.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011